I agree that this site is using cookies. You can find further informations here.
X
Sharkey, Brian J.
579  results:
Search for persons X
?
1

Plain Language Summary of the PAISLEY study: deucravacitini..:

Morand, Eric F. ; Pike, Marilyn ; Merrill, J...
Expert Opinion on Investigational Drugs.  33 (2024)  5 - p. 431-440 , 2024
Link: https://doi.org/10.1080/..
 
?
2

Efficacy and safety of deucravacitinib, an oral, selective,..:

Werth, Victoria ; Pike, Marilyn ; Merrill, Joan...
SKIN The Journal of Cutaneous Medicine.  7 (2023)  2 - p. s114 , 2023
Link: https://doi.org/10.25251..
 
?
3

965: EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELEC..:

Danese, Silvio ; Panaccione, Remo ; D'Haens, Geert R....
Gastroenterology.  162 (2022)  7 - p. S-226-S-227 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic..:

Morand, Eric ; Pike, Marilyn ; Merrill, Joan T....
Arthritis & Rheumatology.  75 (2022)  2 - p. 242-252 , 2022
Link: https://doi.org/10.1002/..
 
?
5

Estimation of the cumulative incidence function under multi..:

Lok, Judith J. ; Yang, Shu ; Sharkey, Brian.
Lifetime Data Analysis.  24 (2017)  2 - p. 201-223 , 2017
Link: https://doi.org/10.1007/..
 
?
6

Nivolumab improved survival vs dacarbazine in patients with..:

Long, Georgina V ; Atkinson, Victoria ; Ascierto, Paolo A...
Journal of Translational Medicine.  13 (2015)  S1 - p. , 2015
Link: https://doi.org/10.1186/..
 
?
7

Physiology of fitness:

Sharkey, Brian J. - 3. ed. . , 1990
Copies:  Zentrale:E02 a kli 035.0/223(3)
 
?
8

RECENT DEVELOPMENTS IN PRODUCTS, GENERAL LIABILITY, AND CON..:

Sharkey, Brian P. ; Coffey, Thomas J. ; DiBiasi, Darren T...
Tort Trial & Insurance Practice Law Journal.  41 (2006)  2 - p. 629-650 , 2006
Link: https://www.jstor.org/st..
 
?
9

THE CLASS ACTION FAIRNESS ACT OF 2005: OVERVIEW, HISTORICAL..:

Reig, Linda Pissott ; Erway III, Charles E. ; Sharkey, Brian P.
Tort Trial & Insurance Practice Law Journal.  40 (2005)  4 - p. 1087-1100 , 2005
Link: https://www.jstor.org/st..
 
?
10

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic..:

Morand, Eric ; Pike, Marilyn ; Merrill, Joan T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100399/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Season 2, Episode 06: Sharkey:

Ruby, Brent ; Sharkey, Brian
https://scholarworks.umt.edu/ontheline_podcasts/16.  , 2018
Link: https://scholarworks.umt..
 
?
12

Estimation of the Cumulative Incidence Function Under Multi..:

Lok, Judith J ; Yang, Shu ; Sharkey, Brian.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572121/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
13

Nivolumab in Previously Untreated Melanoma without BRAF Mut..:

Robert, Caroline ; Long, Georgina V ; Brady, Benjamin...
https://lup.lub.lu.se/record/5190601.  , 2015
Link: https://lup.lub.lu.se/re..
 
?
14

Nivolumab improved survival vs dacarbazine in patients with..:

Long, Georgina V ; Atkinson, Victoria ; Ascierto, Paolo A...
Journal of Translational Medicine. 2015 Jan 15;13(Suppl 1):O6.  , 2015
Link: http://hdl.handle.net/10..
 
?
15

Wildland firefighter health and safety : recommendations of..:

Jukkala, Arthur H ; Sharkey, Brian J ; Technology & Development Program (U.S.)
http://hdl.handle.net/2027/umn.31951d02179764z.  , 1999
Link: http://hdl.handle.net/20..
 
1-15